Table 1.
Baseline population characteristics by genetic variants at PPARG (mean ± SD, t-tests, chi-square tests).
| Omega-3 Fatty Acids (n = 50) | p-Value | Placebo (n = 49) | p-Value | |||
|---|---|---|---|---|---|---|
| PPARG Polymorphism (n = 21) | No PPARG Polymorphism (n = 29) | PPARG Polymorphism (n = 21) | No PPARG Polymorphism (n = 28) | |||
| Age, y | 62.7 ± 6.0 | 63.5 ± 10.1 | p = 0.76 | 60.8 ± 10.4 | 59.5 ± 10.2 | p = 0.69 |
| Women, % | 57.1 | 55.2 | p = 0.71 | 54.5 | 60.7 | p = 0.28 |
| Body mass index, kg/m2 | 28.5 ± 3.2 | 27.9 ± 3.0 | p = 0.68 | 28.7 ± 3.4 | 27.8 ± 2.9 | p = 0.70 |
| 10-y risk ASCVD risk, % | 7.9 | 7.5 | p = 0.75 | 8.2 | 7.3 | p = 0.61 |
| Total cholesterol, mg/dL | 215 ± 25 | 200 ± 22 | p = 0.05 | 220 ± 28 | 198 ± 20 | p = 0.03 |
| LDL-C, mg/dL | 135.3 ± 23.2 | 123.7 ± 19.3 | p = 0.04 | 139.2 ± 27.1 | 119.9 ± 17.8 | p = 0.02 |
| HDL-C, mg/dL | 52.4 ± 13.5 | 61.9 ± 16.6 | p = 0.03 | 51.5 ± 11.6 | 59.2 ± 15.1 | p = 0.05 |
| Triglycerides, mg/dL | 160 ± 35 | 140 ± 25 | p = 0.03 | 165 ± 40 | 135 ± 20 | p = 0.02 |
| hsCRP, mg/L | 2.5 ± 1.7 | 1.9 ± 1.3 | p = 0.20 | 2.6 ± 1.8 | 1.8 ± 1.2 | p = 0.19 |